Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1b/2a study of radiprodil in pediatric TSC or FCD type II with refractory seizures
2023-506301-20-00Phase 2Authorised
- Sponsor
- GRIN Therapeutics, Inc.
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of radiprodil in tuberous sclerosis complex (TSC) and Focal Cortical Dysplasia Type 2 (FCD2) (2 cohorts), sponsored by GRIN Therapeutics, Inc. Primary endpoints: Safety and tolerability and Pharmacokinetics of radiprodil. Planned start Jan 2024; status: authorised.
02
Drugs
radiprodil
03
Conditions
tuberous sclerosis complex (TSC)Focal Cortical Dysplasia Type 2 (FCD2)
Beyond the preview
Go deeper on 2023-506301-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506301-20-00.